



## SMS Lifesciences India Limited

Registered & Corporate Office :

Plot No. 19-III, Road No. 71,  
Opp. Bharatiya Vidya Bhavan Public School,  
Jubilee Hills, Hyderabad - 500 096, Telangana, INDIA.  
Tel : +91-040-6628 8888, Fax : +91-40-2355 1401  
CIN : L74930TG2006PLC050223  
Email : info@smslife.in, Website : www.smslife.in

November 14, 2022

To

**BSE Limited,**

Listing Department, P J Towers,  
Dalal Street,  
Mumbai – 400 001.

**Scrip Code: 540679**

Through: BSE Listing Center

**National Stock Exchange of India Limited,**

Listing Department, "Exchange Plaza",  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Trading Symbol: SMSLIFE**

Through: NSE Digital Exchange

**SUB: OUTCOME OF THE 83<sup>RD</sup> BOARD MEETING.**

**Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

With reference to the above-cited subject, we would like to inform you that the Board of Directors of the Company at its Meeting held today i.e. **November 14, 2022**, have *inter-alia* considered and approved the unaudited [Standalone & Consolidated] financial results for the quarter and half year ended September 30, 2022, as recommended by the Audit Committee.

In this regard, we are enclosing herewith a copy of the following:

Annexure	Particulars
1)	The unaudited financial results (Standalone & Consolidated) for the quarter and half year ended September 30, 2022
2)	The Limited Review Report by the Statutory Auditors on the Un-audited Financial Results (Standalone & Consolidated)
3)	Statement of Assets & Liabilities and Cash-flow statement

The meeting of the Board commenced at **01.30 pm** and concluded at **03.50 pm**.

Please take the same on record and suitably disseminate it to all concerned.

For SMS Lifesciences India Limited

  
**Trupti Ranjan Mohanty**  
Company Secretary



**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smlife.in

**Standalone Statement of Unaudited Financial Results for the Quarter and Half Year Ended 30th September, 2022**

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	7,848.00	8,045.31	8,475.51	15,893.30	15,797.98	34,562.81
2	Other Income	13.08	29.96	65.22	34.64	63.57	153.55
3	<b>Total Revenue</b>	<b>7,861.08</b>	<b>8,075.27</b>	<b>8,540.73</b>	<b>15,927.94</b>	<b>15,861.55</b>	<b>34,716.36</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	4,656.13	5,092.93	6,019.87	9,749.06	10,074.10	21,616.44
	(b) Changes in Inventories	262.64	(439.54)	(1,088.27)	(176.90)	(825.59)	(778.72)
	(c) Manufacturing Expenses	1,157.72	1,324.69	1,501.93	2,482.40	2,740.98	5,832.00
	(d) Employee Benefits Expense	815.92	830.03	790.41	1,645.95	1,527.09	3,251.35
	(e) Finance Cost	124.11	118.12	131.31	242.24	238.15	462.50
	(f) Depreciation and Amortization Expense	203.83	198.94	206.55	402.76	403.21	799.04
	(g) Other Expenses	311.78	347.55	470.55	650.93	784.36	1,505.27
	<b>Total Expenses - (a to g)</b>	<b>7,532.13</b>	<b>7,472.72</b>	<b>8,032.35</b>	<b>14,996.44</b>	<b>14,942.30</b>	<b>32,687.88</b>
5	<b>Profit Before Exceptional and Extraordinary Items and Tax (3-4)</b>	<b>328.95</b>	<b>602.55</b>	<b>508.38</b>	<b>931.50</b>	<b>919.25</b>	<b>2,028.48</b>
6	Exceptional / Extraordinary Items	-	-	777.25	-	777.25	1,269.22
7	<b>Profit Before Tax (5+6)</b>	<b>328.95</b>	<b>602.55</b>	<b>1,285.63</b>	<b>931.50</b>	<b>1,696.50</b>	<b>3,297.70</b>
8	Tax Expenses						
	(1) Current Tax	75.00	200.00	308.00	275.00	430.00	850.00
	(2) Relating to Earlier Year	-	-	-	-	-	(93.98)
	(3) Deferred Tax	(9.27)	(8.03)	3.30	(17.31)	2.36	3.55
		<b>65.73</b>	<b>191.97</b>	<b>311.30</b>	<b>257.69</b>	<b>432.36</b>	<b>759.57</b>
9	<b>Net Profit / (Loss) for the Period (9-10)</b>	<b>263.22</b>	<b>410.58</b>	<b>974.33</b>	<b>673.81</b>	<b>1,264.14</b>	<b>2,538.13</b>
10	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(2.15)	(1.95)	(2.41)	(4.10)	(6.79)	(7.10)
	Income Tax effect on the above	(0.63)	(0.57)	(0.99)	(1.19)	(1.98)	(2.07)
		<b>(1.52)</b>	<b>(1.38)</b>	<b>(1.42)</b>	<b>(2.91)</b>	<b>(4.81)</b>	<b>(5.03)</b>
11	<b>Total Comprehensive Income for the period (11+12)</b>	<b>261.70</b>	<b>409.20</b>	<b>972.91</b>	<b>670.90</b>	<b>1,259.33</b>	<b>2,533.10</b>
12	Earnings Per Equity Share of Rs.10/- each						
	Excluding Exceptional Income						
	Basic / Diluted (not annualised)	8.71	13.58	11.65	22.29	41.81	83.95
	Including Exceptional Income after tax effect thereon						
	Basic / Diluted (not annualised)	8.71	13.58	32.23	22.29	21.23	50.24
	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						14,819.07





**Standalone Un-Audited Statement of Assets and Liabilities as at 30th September, 2022**

(Rs.in Lakhs)


Sr. No.	Particulars	As at	As at
		30.09.2022 (Un Audited)	31.03.2022 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	9,301.67	9,630.36
	(b) Right-of-use Assets	200.58	230.67
	(c) Capital Work-in-Progress	4,272.87	2,120.75
	(d) Intangible Assets	9.54	11.38
	(e) Financial Assets:		
	(i) Investments	2,323.67	2,323.67
	(ii) Other Financial Assets	269.39	228.28
	(f) Other Non-Current Assets	552.93	423.35
	<b>Sub Total :Non-Current Assets</b>	<b>16,930.65</b>	<b>14,968.46</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	7,358.09	8,135.69
	(b) Financial Assets		
	(i) Trade Receivables	4,125.18	3,377.41
	(ii) Cash and Cash Equivalents	25.93	94.64
	(iii) Bank Balances (Other than (ii) above)	134.13	119.12
	(c) Other Current Assets	3,252.79	4,504.73
	<b>Sub Total : Current Assets</b>	<b>14,896.12</b>	<b>16,231.59</b>
	<b>TOTAL ASSETS</b>	<b>31,826.77</b>	<b>31,200.05</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	15,444.62	14,819.07
	<b>Sub-Total -Shareholders' funds</b>	<b>15,746.95</b>	<b>15,121.40</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	4,433.94	2,684.67
	(ii) Lease Liabilities	159.28	185.33
	(b) Provisions	355.36	325.36
	(c) Deferred Tax Liabilities (net)	968.69	987.19
	<b>Sub-Total -Non-Current Liabilities</b>	<b>5,917.26</b>	<b>4,182.55</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	2,886.06	3,289.46
	(ii) Lease Liabilities	50.68	47.89
	(iii) Trade Payables:		
	(a) Dues to Micro & Small Enterprises	55.00	81.70
	(b) Dues to Creditors Otherthan Micro & Small Enterprises	5,049.21	7,003.09
	(iv) Other Financial Liabilities	1,112.24	883.95
	(b) Provisions	97.33	97.33
	(c) Other Current Liabilities	722.14	363.55
	(d) Current Tax Liabilities (Net)	189.88	129.13
	<b>Sub-Total - Current Liabilities</b>	<b>10,162.56</b>	<b>11,896.10</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>31,826.77</b>	<b>31,200.05</b>



**SMS LifeSciences India Limited**
**Standalone Statement of Cash Flow for the Half Year Ended 30th September, 2022**

(All amounts in Indian Rupees, unless otherwise stated)

Particulars	For the Half Year ended 30th Sept, 2022	For the Year ended 31st March, 2022
<b>A Cash Flow from Operating Activities</b>		
Profit Before Income Tax	931.50	2,028.48
<b>Adjustments for:</b>		
Depreciation and amortisation expense	402.76	799.04
Interest Income classified as Investing Cash Flows	(2.99)	(6.97)
Allowance for Doubtful Debts	40.22	21.32
Interest on Non Current Borrowings	74.54	154.88
Interest on Unsecured Loans	20.79	42.83
Provision for Employee Benefits	25.90	40.84
Term Loan Processing Fee	1.01	1.54
Loss on Sale of Assets	0.12	0.41
Profit on Sale Of Assets.	-	(9.07)
Interest on Leased Premises	12.73	6.79
	<b>1,506.58</b>	<b>3,080.09</b>
<b>Change in Operating Assets and Liabilities</b>		
(Increase)/Decrease in Trade Receivables	(787.98)	(399.31)
(Increase)/Decrease in Inventories	777.60	(2,259.57)
Increase/(Decrease) in Trade Payables	(1,980.57)	1,492.09
(Increase)/Decrease in Other Non Current Financial Assets	(41.10)	(10.77)
(Increase)/Decrease in Other Non Current Asset	(129.58)	(86.62)
(Increase)/Decrease in Other Current Financial Assets	-	(15.67)
(Increase)/Decrease in Other Current Asset	1,251.93	(727.81)
(Increase) Decrease in Prepaid Taxes	(14.25)	44.45
Increase/(Decrease) in Other Current Financial Liabilities	54.05	15.67
Increase/(Decrease) in Other Non Current Liabilities	-	(600.00)
Increase/(Decrease) in Other Current Liabilities	358.59	(1,242.08)
	<b>(511.31)</b>	<b>(3,789.62)</b>
<b>Cash generated from Operations</b>	995.27	(709.53)
Income Taxes Paid	(200.00)	(756.02)
<b>Net Cash Inflow from Operating Activities "A"</b>	<b>795.27</b>	<b>(1,465.55)</b>
<b>B Cash flows from Investing Activities</b>		
Purchase for Property, Plant and Equipment	(2,062.17)	(2,496.42)
Proceeds from sale of Property, Plant and Equipment	43.56	953.12
Proceeds from sale of Investments	-	749.70
Margin Money Deposits	(28.02)	37.68
Interest Received on Margin Money Deposit	0.66	6.97
<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(2,045.97)</b>	<b>(748.95)</b>
<b>C Cash flows from Financing Activities</b>		
Proceeds from Long Term Borrowings	2,102.71	1,169.46
Repayment of Long Term Borrowings	(279.44)	(328.73)
Proceeds from Short Term Borrowings	-	693.92
Repayment of Short term Borrowings	(478.40)	-
Repayment of Lease Liability	(23.27)	178.66
Interest paid	(94.25)	(205.18)
Dividends paid to company's shareholders	(45.35)	(45.35)
<b>Net Cash (Outflow) from Financing Activities "C"</b>	<b>1,182.00</b>	<b>1,462.80</b>
<b>Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(68.71)</b>	<b>(751.69)</b>
Cash and Cash Equivalents at the beginning of the Financial Year / Period	94.64	846.35
<b>Cash and Cash Equivalents at End of the Year / Period</b>	<b>25.93</b>	<b>94.64</b>





**Notes:**

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 14th November, 2022 and have been approved by the Board of Directors at its meeting held on 14th November, 2022. The statutory auditors of the Company have carried out a limited review of Standalone financial results for the half year ended 30th September, 2022 and expressed an unmodified opinion thereon.
- 2 The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 14-11-2022

**For SMS Lifesciences India Limited**

**TVVSN Murthy**  
**Managing Director**  
**DIN: 00465198**



**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

**Review Report to  
The Board of Directors  
SMS Lifesciences India Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of **SMS Lifesciences India Limited** ("the Company"), for the quarter ended 30<sup>th</sup> September 2022 and year to date from 01<sup>st</sup> April 2022 to 30<sup>th</sup> September 2022 ("the statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of the interim financial information consists of making inquiries primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 14-11-2022

UDIN: 22026548BDAOSG5031

For Rambabu & Co.,  
Chartered Accountants  
Reg. No. 002976S

  
GVL Prasad  
Partner  
M.No. 026548





**SMS LIFESCIENCES INDIA LIMITED**

(CIN: L74930TH2006PLC050223)


Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

**Consolidated Statement of UnAudited Financial Results for the Quarter and Half Year Ended 30th September, 2022**

(Rs. In Lakhs)


S.No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	8,125.98	8,227.58	8,675.12	16,353.56	16,275.12	34,974.45
2	Other Income	14.92	30.91	66.92	37.40	67.81	206.65
3	<b>Total Revenue</b>	<b>8,140.90</b>	<b>8,258.49</b>	<b>8,742.04</b>	<b>16,390.96</b>	<b>16,342.93</b>	<b>35,181.10</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	4,253.77	4,857.86	5,810.14	9,105.05	9,741.04	20,447.12
	(b) Changes in Inventories	332.85	(396.72)	(1,282.20)	(57.29)	(1,032.44)	(978.55)
	(c) Manufacturing Expenses	1,353.53	1,526.03	1,736.97	2,879.56	3,119.68	6,507.39
	(d) Employee Benefits Expense	1,022.57	1,027.40	966.64	2,049.96	1,847.94	3,990.21
	(e) Finance Cost	168.09	163.82	181.64	331.91	293.51	617.39
	(f) Depreciation and Amortization Expense	264.25	258.70	268.91	522.96	481.59	1,000.60
	(g) Other Expenses	336.05	364.40	482.57	692.01	811.30	1,593.07
	<b>Total Expenses - (a to h)</b>	<b>7,731.11</b>	<b>7,801.49</b>	<b>8,164.67</b>	<b>15,524.16</b>	<b>15,262.62</b>	<b>33,177.23</b>
5	<b>Profit Before Exceptional and Extraordinary Items and Tax (3-4)</b>	<b>409.79</b>	<b>457.00</b>	<b>577.37</b>	<b>866.80</b>	<b>1,080.31</b>	<b>2,003.87</b>
6	Exceptional / Extraordinary Items	-	-	777.25	-	777.25	1,269.22
7	<b>Profit Before Tax (5+6)</b>	<b>409.79</b>	<b>457.00</b>	<b>1,354.62</b>	<b>866.80</b>	<b>1,857.56</b>	<b>3,273.09</b>
8	Tax Expenses						
	(1) Current Tax	75.00	200.00	288.00	275.00	430.00	850.00
	(2) Relating to Earlier Year	-	-	-	-	-	(94.13)
	(3) Mat Credit Entitlement	-	-	-	-	-	-
	(4) Deferred Tax	22.48	24.90	41.37	47.39	39.55	(12.76)
		<b>97.48</b>	<b>224.90</b>	<b>329.37</b>	<b>322.39</b>	<b>469.55</b>	<b>743.11</b>
9	<b>Net Profit / (Loss) for the Period (7-8)</b>	<b>312.31</b>	<b>232.10</b>	<b>1,025.25</b>	<b>544.41</b>	<b>1,388.01</b>	<b>2,529.98</b>
10	<b>Other Comprehensive Income/(Loss) (OCI):</b>						
	(A) Items that will not be reclassified to statement of Profit & Loss						
	Remeasurement of post-employment benefit obligations	(1.70)	2.57	(1.82)	(3.24)	(5.66)	(5.09)
	Income Tax effect on the above	(0.51)	1.06	(0.82)	(0.97)	(1.66)	(1.51)
12	Other Comprehensive Income/(Loss) after tax for the Period / Year (13-14)	(1.19)	1.51	(0.99)	(2.27)	(4.00)	(3.58)
13	<b>Total comprehensive Income for the period/year (14+18)</b>	<b>311.12</b>	<b>233.61</b>	<b>1,024.25</b>	<b>542.14</b>	<b>1,384.01</b>	<b>2,526.40</b>
	<b>Profit for the year attributable to:</b>						
	Equity holders of the parent	275.17	300.86	1,025.25	576.04	1,388.01	2,532.22
	Non-controlling interests	37.13	(68.76)	-	(31.63)	-	(2.23)
	<b>Total comprehensive income for the year attributable to:</b>						
	Equity holders of the parent	273.98	302.37	1,024.25	573.77	1,384.01	2,528.64
	Non-controlling interests	37.13	(68.76)	-	(31.63)	-	(2.23)
14	Earning Per Equity Share of Rs.10/- each						
	Excluding Exceptional Income	10.33	9.95	13.33	19.05	25.33	49.90
	Basic / Diluted (not annualised) (Refer Note No.4)						
	Including Exceptional Income after tax effect thereon	10.33	7.68	33.91	-	45.91	83.76
	Basic / Diluted (not annualised)						
15	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
16	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						14,920.90



**Consolidated Un-Audited Statement of Assets and Liabilities as at 30th September, 2022**

(Rs.in Lakhs)

Sr. No.	Particulars	As at	As at
		30.09.2022 (Unaudited)	31.03.2022 (Audited)
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-Current Assets</b>		
	(a) Property, Plant and Equipment	13,510.54	13,960.68
	(b) Right-of-use Assets	200.58	230.66
	(c) Capital Work-in-Progress	8,182.76	5,118.04
	(d) Intangible Assets	9.54	11.38
	(e) Financial Assets:		
	(i) Investments	4.11	4.11
	(iii) Other Financial Assets	312.38	271.27
	(f) Other Non-Current Assets	579.24	477.08
	<b>Sub Total :Non-Current Assets</b>	<b>22,799.15</b>	<b>20,073.22</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	7,817.96	8,481.11
	(b) Financial Assets		
	(i) Trade Receivables	4,396.11	3,383.16
	(ii) Cash and Cash Equivalents	55.66	98.60
	(iii) Bank Balances (Other than (ii) above)	355.61	340.60
	(c) Other Current Assets	2,097.50	3,298.09
	<b>Sub Total : Current Assets</b>	<b>14,722.84</b>	<b>15,601.56</b>
	<b>TOTAL ASSETS</b>	<b>37,521.99</b>	<b>35,674.78</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity:</b>		
	(a) Equity Share Capital	302.33	302.33
	(b) Other Equity	15,982.94	14,920.90
	<b>Equity Attributable to Share Holders of the company</b>	<b>16,285.27</b>	<b>15,223.23</b>
	Non Cotroling Interest	1,938.37	1,269.70
	<b>Sub-Total -Shareholders' funds</b>	<b>18,223.64</b>	<b>16,492.93</b>
	<b>Liabilities:</b>		
<b>2</b>	<b>Non-Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	5,556.79	4,033.20
	(ii) Lease Liabilities	159.27	185.33
	(b) Provisions	385.73	350.84
	(c) Deferred Tax Liabilities (Net)	1,114.85	1,068.43
	<b>Sub-Total -Non-Current Liabilities</b>	<b>7,216.64</b>	<b>5,637.80</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	3,338.50	3,693.33
	(ii) Lease Liabilities	50.68	47.89
	(ii) Trade Payables:		
	(a) Trade Payables - MSME	69.98	89.36
	(b) Trade Payables - Otherthan MSME	5,580.00	7,699.79
	(iii) Other Financial Liabilities	1,741.68	1,262.39
	(b) Provisions	98.55	98.45
	(c) Other Current Liabilities	1,066.57	565.10
	(d) Current Tax Liabilities (Net)	135.75	87.74
	<b>Sub-Total - Current Liabilities</b>	<b>12,081.71</b>	<b>13,544.05</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>37,521.99</b>	<b>35,674.78</b>





# SMS LifeSciences India Limited

Consolidated Statement of Cash Flow for the Half Year Ended 31th September, 2022

(All amounts in Indian Rupees, unless otherwise stated)

Particulars	For the Half Year ended 30.09.2022	For the Year ended 31.03.2022
<b>A Cash Flow from Operating Activities</b>		
Profit Before Income Tax	866.80	2,003.87
<b>Adjustments for:</b>		
Depreciation and amortisation expense	522.96	1,000.60
Interest Income classified as Investing Cash Flows	(2.99)	(21.16)
Allowance for Doubtful Debts	40.22	21.32
Interest on Non Current Borrowings	163.32	303.85
Interest on Unsecured Loans	20.79	42.83
Provision for Employee Benefits	31.76	58.03
Term Loan Processing Fee	1.01	1.54
Profit on Sale of Assets	-	(9.07)
Loss on Sale of Assets	0.12	0.41
Interest On Leased Premises	12.73	6.79
	<b>1,656.72</b>	<b>3,409.02</b>
<b>Change in Operating Assets and Liabilities</b>		
(Increase)/Decrease in Trade Receivables	(1,003.48)	10.53
(Increase)/Decrease in Inventories	727.77	(2,419.50)
Increase/(Decrease) in Trade Payables	(1,588.50)	1,735.71
(Increase)/Decrease in Other Non Current Financial Assets	(41.10)	(24.32)
(Increase)/Decrease in Other Non Current Asset	(75.85)	(33.13)
(Increase)/Decrease in Other Current Financial Assets	-	(28.25)
(Increase)/Decrease in Other Current Asset	(473.41)	(2,793.63)
(Increase) Decrease in Prepaid Taxes	(27.00)	44.45
Increase/(Decrease) in Other Non Current Liabilities	-	(600.00)
Increase/(Decrease) in Other Current Financial Liabilities	54.05	15.67
Increase/(Decrease) in Other Current Liabilities	2,149.15	330.12
	<b>(278.37)</b>	<b>(3,762.35)</b>
<b>Cash generated from Operations</b>	1,378.35	(353.33)
Income Taxes Paid	(200.00)	(770.77)
<b>Net Cash Inflow from Operating Activities "A"</b>	<b>1,178.35</b>	<b>(1,124.10)</b>
<b>B Cash flows from Investing Activities</b>		
Purchase for Property, Plant and Equipment	(3,279.25)	(5,115.31)
Proceeds from sale of Property, Plant and Equipment	49.61	963.58
Proceeds from sale of Investments	1,119.62	3,378.59
Margin Money Deposits	(28.02)	37.68
Fixed Deposits Made	0.01	-
Interest Received on Margin Money Deposit	0.66	21.17
<b>Net Cash Outflow from Investing Activities "B"</b>	<b>(2,137.37)</b>	<b>(714.28)</b>
<b>C Cash flows from Financing Activities</b>		
Proceeds from Long Term Borrowings	2,102.71	1,169.46
Repayment of Long Term Borrowings	(505.13)	(731.49)
Proceeds from Short Term Borrowings	48.57	866.22
Repayment of Short term Borrowings	(478.40)	-
Repayment of Lease Liability	(23.27)	178.66
Interest paid	(183.03)	(354.15)
Dividend paid to company's shareholders	(45.35)	(45.35)
<b>Net Cash (Outflow) from Financing Activities "C"</b>	<b>916.10</b>	<b>1,083.35</b>
<b>Net Increase (Decrease) in Cash and Cash Equivalents (A+B+C)</b>	<b>(42.93)</b>	<b>(755.03)</b>
Cash and Cash Equivalents at the beginning of the Financial Year	98.60	853.63
<b>Cash and Cash Equivalents at End of the Period / Year</b>	<b>55.66</b>	<b>98.60</b>



**Notes:**

- 1 The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 14th November, 2022 and have been approved by the Board of Directors at its meeting held on 14th November, 2022. The statutory auditors of the Company have carried out a limited review of Consolidated financial results for the quarter and half year ended 30th September, 2022 and expressed an unmodified conclusion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The Consolidated financial results include the appropriate share in financial results of Mahi Drugs Private Limited a subsidiary, with 60% stake are prepared by applying Ind AS 110- "Consolidated Financial Statements".
- 4 The Consolidated entity is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 5 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad  
Date : 14-11-2022

**For SMS Lifesciences India Limited**

**TVVSN Murthy**  
Managing Director  
DIN : 00465198





**Independent Auditor's Review Report on review of Interim Consolidated Financial Results**

To the Board of Directors of  
**SMS Lifesciences India Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SMS Lifesciences India Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> September, 2022 and year to date from 01<sup>st</sup> April 2022 to 30<sup>th</sup> September 2022 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by The Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. SMS Lifesciences India Limited
- b. M/s. Mahi Drugs Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs. 1,014.85 lakhs, total net profit after tax of Rs.92.19 lakhs and total comprehensive income of Rs.92.53 lakhs for the Quarter ended 30 September, 2022, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad

Date: 14-11-2022

For Rambabu & Co.,

Chartered Accountants

Reg. No.002976S

  
GVL Prasad

Partner

M. No. 026548

UDIN: 22026548BDAMZG8325

